WO2000035493A3 - Verfahren zur lokalisierung von krankheitsherden - Google Patents

Verfahren zur lokalisierung von krankheitsherden Download PDF

Info

Publication number
WO2000035493A3
WO2000035493A3 PCT/EP1999/009925 EP9909925W WO0035493A3 WO 2000035493 A3 WO2000035493 A3 WO 2000035493A3 EP 9909925 W EP9909925 W EP 9909925W WO 0035493 A3 WO0035493 A3 WO 0035493A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
site
localizing
patient
antibodies
Prior art date
Application number
PCT/EP1999/009925
Other languages
English (en)
French (fr)
Other versions
WO2000035493A2 (de
Inventor
Georg S Wengler
Original Assignee
Georg S Wengler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg S Wengler filed Critical Georg S Wengler
Publication of WO2000035493A2 publication Critical patent/WO2000035493A2/de
Publication of WO2000035493A3 publication Critical patent/WO2000035493A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Lokalisierung von Krankheitsherden im Körper von menschlichen oder tierischen Patienten, bei dem Patienten Abwehrzellen mit den zugeordneten Antikörpern zu einem Zell-Antikörper-Komplex verbunden werden, wobei die Antikörper mit kontrastgebenden Partikeln gelabelt sind. Der Krankheitsherd wird mit Hilfe eines bildgebenden Verfahrens ermittelt, die zum Krankheitsherd im Körper des Patienten gewanderten Zell-Antikörper-Komplexe ermittelt.
PCT/EP1999/009925 1998-12-14 1999-12-14 Verfahren zur lokalisierung von krankheitsherden WO2000035493A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998157618 DE19857618A1 (de) 1998-12-14 1998-12-14 Verfahren zur Lokalisierung von Krankheitsherden
DE19857618.8 1998-12-14

Publications (2)

Publication Number Publication Date
WO2000035493A2 WO2000035493A2 (de) 2000-06-22
WO2000035493A3 true WO2000035493A3 (de) 2000-09-21

Family

ID=7891021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009925 WO2000035493A2 (de) 1998-12-14 1999-12-14 Verfahren zur lokalisierung von krankheitsherden

Country Status (2)

Country Link
DE (1) DE19857618A1 (de)
WO (1) WO2000035493A2 (de)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010463A1 (en) * 1989-03-14 1990-09-20 Neorx Corporation Imaging tissue sites of inflammation
WO1991014453A1 (en) * 1990-03-27 1991-10-03 Thomas Jefferson University Improved method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1994007138A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
WO1995009013A1 (en) * 1993-09-28 1995-04-06 Cytogen Corporation Metal-binding targeted polypeptide constructs
WO1998000560A2 (en) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
WO1998057665A2 (en) * 1997-03-18 1998-12-23 Oxford Biomedica (Uk) Limited The use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624426A1 (de) * 1996-06-19 1998-01-02 Christian Bergemann Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010463A1 (en) * 1989-03-14 1990-09-20 Neorx Corporation Imaging tissue sites of inflammation
WO1991014453A1 (en) * 1990-03-27 1991-10-03 Thomas Jefferson University Improved method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1994007138A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
WO1995009013A1 (en) * 1993-09-28 1995-04-06 Cytogen Corporation Metal-binding targeted polypeptide constructs
WO1998000560A2 (en) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
WO1998057665A2 (en) * 1997-03-18 1998-12-23 Oxford Biomedica (Uk) Limited The use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue

Also Published As

Publication number Publication date
WO2000035493A2 (de) 2000-06-22
DE19857618A1 (de) 2000-06-21

Similar Documents

Publication Publication Date Title
GR3035717T3 (en) Tie-2 ligands, methods of making and uses thereof
AU6341298A (en) Ultrasonic catheter, system and method for two-dimensional imaging or three-dimensional reconstruction
WO2001036972A3 (en) Elisa for vegf
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
EP1357131A3 (de) Behandlung von Lupus-Nephritis mit Anti-CD40L-Verbindungen
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP0953326A3 (de) Damenbinde
WO2004065547A3 (en) Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
CA2212058A1 (en) Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease
EP0787476A3 (de) Gerät zum Aktivieren von Zellen eines menschlichen Körpers
EP1808155A3 (de) Hybride Antikörperserumproteine
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
AU6416198A (en) Diagnostic means useful for predictive assessment of human hepatocellular carc inoma disease (hcc), as well as diagnostic methods using the same
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
AU5328299A (en) Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
WO1997011667A3 (en) Therapeutic applications using horse serum
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
AU5153398A (en) Diagnostic method for the detection of alzheimer's disease in living patients
EP1420066A3 (de) Verwendung von Fullerene Derivaten als DNA -Verdichtungsmittel
WO2000035493A3 (de) Verfahren zur lokalisierung von krankheitsherden
EP1293214A3 (de) LTB4 Antagonisten und Radiopharmazeutika für Bilderzeugung der Infektion und Entzündung
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003253298A1 (en) System and method of processing electromyographic signals for the diagnosis of parkinson's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase